Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Biotechnology 25, 363 (1 April 2007) | doi:10.1038/nbt0407-363
Sacrificing the cash cow
Abstract
Amgen must be longing for the days when the only worry for its EPO products, Epogen and Aranesp, was how to sell more drug to more patients. But now it looks as if it is going to fall foul of a familiar pharmaceutical malaise—overextension of its franchise.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
